Öйú365betÖÐÎĹÙÍø

Bimatoprost is an almost 20-year-old drug that has medical and cosmetic uses, both pertaining to the eyes. It is closely related to the prostaglandin family of hormones.

In 2001, the US Food and Drug Administration approved a new drug application from Allergan (Irvine, CA) for using bimatoprost eyedrops to lower intraocular pressure in patients suffering from open-angle glaucoma. Seven years later, FDA approved Allergan’s application for a cosmetic use of bimatoprost: increasing the length, thickness, and darkness of eyelashes. Just last year, FDA accepted Allergan’s application for a sustained-release bimatoprost implant that lets glaucoma patients avoid the need for eyedrops.

Bimatoprost has several adverse side effects. The most frequent one is conjunctivitis, which occurs in more than 10% of patients. Others include blurred vision, redness, burning, and darkening of the iris. Eyelid infection and darkening can occur when the drug is used on eyelashes.

In 2015, Diego Romano and co-workers at the University of Milan (Italy) reported an and its cousin latanoprost that uses enzymatic reactions. Then, in 2019, bimatoprost was a “guinea pig� during the development of a synthesis-planning program that combines human knowledge with machine learning.

In 2012, Bartosz A. Grzybowski of the Ulsan National Institute of Science and Technology (South Korea) and the Polish Academy of Sciences (Warsaw) published Chematica, a program that uses chemical information to generate synthetic sequences. Grzybowski and colleagues updated Chematica by that use the software’s database and chemistry experts� insights to optimize the practicality of the reaction sequences it produces.

Significantly, the hybrid version of Chematica can identify seldom-used reactions to generate sequences that the original version was unable to find. Bimatoprost synthesis is an example of the use of reactions that did not show up before the original Chematica program was “trained�.